Business
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
SAN DIEGO, April 30, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Acadia of her plans. She will continue in her role as Head of Research and Development until a successor is appointed. After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and le
About this update from Acadia Pharmaceuticals Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":800,"height":307,"url":"https://media.zenfs.com/en/business-wire.com/32740dbb9f3fe421a42e6275b3e57f76"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GRZUy5wfR0GXCImC_t158Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2OA--/https://media.zenfs.com/en/business-wire.com/32740dbb9f3fe421a42e6275b3e57f76","width":800,"height":307},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/KD8Sxkdm.vr5FMOK1.IrWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2MDA7aD02MTQ-/https://media.zenfs.com/en/business-wire.com/32740dbb9f3fe421a42e6275b3e57f76","width":800,"height":307}},"lazy":false},{"type":"text","content":"SAN DIEGO, April 30, 2026--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Acadia of her plans. She will continue in her role as Head of Research and Development until a successor is appointed. After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and leadership continuity through the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer’s disease psychosis (ADP) and into early Phase 3 clinical study execution.","length":699,"tagName":"p"},{"type":"text","content":"Acadia has initiated a search for a new Head of Research and Development and is committed to identifying an experienced R&D leader who will build on the strong scientific foundation already in place. The Company continues to advance its clinical development programs as planned. All ongoing clinical trials, including the Phase 2 studies of remlifanserin in ADP and Lewy Body Dementia Psychosis (LBDP), continue to recruit and remain blinded, and the Company, including Dr. Thompson, does not yet know study outcomes.","length":521,"tagName":"p"},{"type":"text","content":""Liz’s leadership has been instrumental in strengthening Acadia’s research and development organization, both scientifically and operationally, and in advancing a clear, disciplined R&D strategy across our pipeline," said Catherine Owen Adams, Chief Executive Officer of Acadia. "She has been a st...